Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fluorouracil, quantity: 40 mg/g - cream - excipient ingredients: stearoyl macrogolglycerides; butylated hydroxytoluene; cetyl alcohol; citric acid; glycerol; isopropyl myristate; methyl hydroxybenzoate; propyl hydroxybenzoate; purified water; arachis oil; sodium hydroxide; stearic acid; stearyl alcohol; methyl gluceth-10 - tolak 4% once daily is indicated for the topical treatment of actinic keratosis (ak) of the face, ears, and/or scalp in adults.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

cvn pharma pty ltd - fluorouracil, quantity: 5 % w/w - cream - excipient ingredients: white soft paraffin; methyl hydroxybenzoate; propyl hydroxybenzoate; polysorbate 60; stearyl alcohol; purified water; propylene glycol - solar and senile keratoses, bowen's disease.

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - fluorouracil - cream - 5 percent weight/weight - pyrimidine analogues; fluorouracil

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/g - cream - excipient ingredients: polysorbate 60; methyl hydroxybenzoate; purified water; stearyl alcohol; white soft paraffin; propylene glycol; propyl hydroxybenzoate - solar and senile keratoses, bowen's disease.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/g - cream - excipient ingredients: polysorbate 60; methyl hydroxybenzoate; purified water; stearyl alcohol; white soft paraffin; propylene glycol; propyl hydroxybenzoate - solar and senile keratoses, bowen's disease.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - fluorouracil, quantity: 50 mg/g - cream - excipient ingredients: methyl hydroxybenzoate; propyl hydroxybenzoate; polysorbate 60; white soft paraffin; purified water; propylene glycol; stearyl alcohol - indications as at 30 july 1990: solar and senile keratoses, bowen's disease.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - fluorouracil 5%;   - topical cream - 5 % - active: fluorouracil 5%   excipient: methyl hydroxybenzoate polysorbate 60 propyl hydroxybenzoate propylene glycol purified water stearyl alcohol white soft paraffin - efudix is used for the topical treatment of superficial pre-malignant and malignant skin lesions; keratoses including senile, actinic and arsenical forms; keratoacanthoma; bowen's disease; superficial basal-cell carcinoma. deep, penetrating or nodular basal cell and squamous cell carcinomas do not usually respond to efudix therapy. it should be used only as a palliative therapy in such cases where no other form of treatment is possible.

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

meda health sales ireland limited - fluorouracil - cream - 5 %w/w - pyrimidine analogues

Marekani - Kiingereza - NLM (National Library of Medicine)

avkare, inc. - levomefolate calcium (unii: a9r10k3f2f) (levomefolic acid - unii:8s95dh25xc), pyridoxal phosphate anhydrous (unii: f06sge49m6) (pyridoxal phosphate anhydrous - unii:f06sge49m6), methylcobalamin (unii: br1sn1js2w) (methylcobalamin - unii:br1sn1js2w) - levomefolate calcium 3 mg - hyperhomocysteinemia of any etiology. medical foods are intended for the patient who has a limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foodstuffs or certain nutrients, or who has other special medically determined nutrient requirements, the dietary management of which cannot be achieved by the modification of the normal diet alone1 . l-methyl-b6-b12 is a specially formulated medical food for the dietary support of patients with hyperhomocysteinemia. it also is helpful in managing patients with high total homocysteine concentrations associated with malabsorption of vitamin b12 or suboptimal intake of b vitamins. l-methyl-b6-b12 tablets should always be used under medical supervision. l-methyl-b6∙b12 is contraindicated in patients with known hypersensitivity to any of the components contained in this product. discontinue use if patient exhibits signs of hypersensitivity such as tachycardia, urticaria, or shortness of breath.

Marekani - Kiingereza - NLM (National Library of Medicine)

virtus pharmaceuticals llc - levomefolate calcium (unii: a9r10k3f2f) (levomefolic acid - unii:8s95dh25xc), pyridoxal phosphate anhydrous (unii: f06sge49m6) (pyridoxal phosphate anhydrous - unii:f06sge49m6), methylcobalamin (unii: br1sn1js2w) (methylcobalamin - unii:br1sn1js2w) - levomefolate calcium 3 mg - hyperhomocysteinemia of any etiology. medical foods are intended for the patient who has a limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foodstuffs or certain nutrients, or who has other special medically determined nutrient requirements, the dietary management of which cannot be achieved by the modification of the normal diet alone1 . l-methyl-b6-b12 is a specially formulated medical food for the dietary support of patients with hyperhomocysteinemia. it also is helpful in managing patients with high total homocysteine concentrations associated with malabsorption of vitamin b12 or suboptimal intake of b vitamins. l-methyl-b6-b12 tablets should always be used under medical supervision. l-methyl-b6∙b12 is contraindicated in patients with known hypersensitivity to any of the components contained in this product. discontinue use if patient exhibits signs of hypersensitivity such as tachycardia, urticaria, or shortness of breath.